Cargando…
Individual-level needle and syringe coverage in Melbourne, Australia: a longitudinal, descriptive analysis
BACKGROUND: Coverage is used as one indicator of needle and syringe program (NSP) effectiveness. At the individual level, coverage is typically defined as an estimate of the proportion of a person who injects drugs’ (PWID) injecting episodes that utilise a sterile syringe. In this paper, we explore...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4992312/ https://www.ncbi.nlm.nih.gov/pubmed/27542604 http://dx.doi.org/10.1186/s12913-016-1668-z |
_version_ | 1782448998144016384 |
---|---|
author | O’Keefe, Daniel Scott, Nick Aitken, Campbell Dietze, Paul |
author_facet | O’Keefe, Daniel Scott, Nick Aitken, Campbell Dietze, Paul |
author_sort | O’Keefe, Daniel |
collection | PubMed |
description | BACKGROUND: Coverage is used as one indicator of needle and syringe program (NSP) effectiveness. At the individual level, coverage is typically defined as an estimate of the proportion of a person who injects drugs’ (PWID) injecting episodes that utilise a sterile syringe. In this paper, we explore levels of individual syringe coverage and its changes over time. METHODS: Data were extracted from 1889 interviews involving 502 participants drawn from the Melbourne drug user cohort study (MIX). We asked questions relating to participants syringe acquisition, distribution and injecting frequency within the two weeks before interview. We created a dichotomous coverage variable that classified participants as sufficiently (≥100 %) covered if all their injecting episodes utilised at least one sterile syringe, and insufficiently (<100 %) covered if not. We categorised participants as “consistently covered” if they were sufficiently covered across interviews; as “consistently uncovered” if they were insufficiently covered across interviews; and “inconsistently covered” if they oscillated between coverage states. Chi-square statistics tested proportions of insufficient coverage across sub-groups using broad demographic, drug use and service utilisation domains. Logistic regression tested predictors of insufficient coverage and inconsistently covered categorisation. RESULTS: Across the sample, levels of insufficient coverage were substantial (between 22–36 % at each interview wave). The majority (50 %) were consistently covered across interviews, though many (45 %) were inconsistently covered. We found strong statistical associations between insufficient coverage and current hepatitis C virus (HCV) infection (RNA+). Current prescription of opioid substitution therapy (OST) and using NSPs as the main source of syringe acquisition were protective against insufficient coverage. CONCLUSION: Insufficient coverage across the sample was substantial and mainly driven by those who oscillated between states of coverage, suggesting the presence of temporal factors. We recommend a general expansion of NSP services and OST prescription to encourage increases in syringe coverage. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12913-016-1668-z) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4992312 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-49923122016-08-21 Individual-level needle and syringe coverage in Melbourne, Australia: a longitudinal, descriptive analysis O’Keefe, Daniel Scott, Nick Aitken, Campbell Dietze, Paul BMC Health Serv Res Research Article BACKGROUND: Coverage is used as one indicator of needle and syringe program (NSP) effectiveness. At the individual level, coverage is typically defined as an estimate of the proportion of a person who injects drugs’ (PWID) injecting episodes that utilise a sterile syringe. In this paper, we explore levels of individual syringe coverage and its changes over time. METHODS: Data were extracted from 1889 interviews involving 502 participants drawn from the Melbourne drug user cohort study (MIX). We asked questions relating to participants syringe acquisition, distribution and injecting frequency within the two weeks before interview. We created a dichotomous coverage variable that classified participants as sufficiently (≥100 %) covered if all their injecting episodes utilised at least one sterile syringe, and insufficiently (<100 %) covered if not. We categorised participants as “consistently covered” if they were sufficiently covered across interviews; as “consistently uncovered” if they were insufficiently covered across interviews; and “inconsistently covered” if they oscillated between coverage states. Chi-square statistics tested proportions of insufficient coverage across sub-groups using broad demographic, drug use and service utilisation domains. Logistic regression tested predictors of insufficient coverage and inconsistently covered categorisation. RESULTS: Across the sample, levels of insufficient coverage were substantial (between 22–36 % at each interview wave). The majority (50 %) were consistently covered across interviews, though many (45 %) were inconsistently covered. We found strong statistical associations between insufficient coverage and current hepatitis C virus (HCV) infection (RNA+). Current prescription of opioid substitution therapy (OST) and using NSPs as the main source of syringe acquisition were protective against insufficient coverage. CONCLUSION: Insufficient coverage across the sample was substantial and mainly driven by those who oscillated between states of coverage, suggesting the presence of temporal factors. We recommend a general expansion of NSP services and OST prescription to encourage increases in syringe coverage. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12913-016-1668-z) contains supplementary material, which is available to authorized users. BioMed Central 2016-08-19 /pmc/articles/PMC4992312/ /pubmed/27542604 http://dx.doi.org/10.1186/s12913-016-1668-z Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article O’Keefe, Daniel Scott, Nick Aitken, Campbell Dietze, Paul Individual-level needle and syringe coverage in Melbourne, Australia: a longitudinal, descriptive analysis |
title | Individual-level needle and syringe coverage in Melbourne, Australia: a longitudinal, descriptive analysis |
title_full | Individual-level needle and syringe coverage in Melbourne, Australia: a longitudinal, descriptive analysis |
title_fullStr | Individual-level needle and syringe coverage in Melbourne, Australia: a longitudinal, descriptive analysis |
title_full_unstemmed | Individual-level needle and syringe coverage in Melbourne, Australia: a longitudinal, descriptive analysis |
title_short | Individual-level needle and syringe coverage in Melbourne, Australia: a longitudinal, descriptive analysis |
title_sort | individual-level needle and syringe coverage in melbourne, australia: a longitudinal, descriptive analysis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4992312/ https://www.ncbi.nlm.nih.gov/pubmed/27542604 http://dx.doi.org/10.1186/s12913-016-1668-z |
work_keys_str_mv | AT okeefedaniel individuallevelneedleandsyringecoverageinmelbourneaustraliaalongitudinaldescriptiveanalysis AT scottnick individuallevelneedleandsyringecoverageinmelbourneaustraliaalongitudinaldescriptiveanalysis AT aitkencampbell individuallevelneedleandsyringecoverageinmelbourneaustraliaalongitudinaldescriptiveanalysis AT dietzepaul individuallevelneedleandsyringecoverageinmelbourneaustraliaalongitudinaldescriptiveanalysis |